Where people have type 2 diabetes, some of the newer antidiabetes drugs, the SGLT2 inhibitors and GLP-1 receptor agonists, have demonstrated cardiovascular benefit and well as some benefits on renal outcomes.[31] Taken together, the results from this study suggest that may be a place for these and other therapies in the management of diabetics with renal disease given their excess risk of cardiovascular outcomes. Here, SLC5A2 is linked to type 2 diabetes mellitus.